Sirtris Pharmaceuticals Announces the Appointment of Paul A. Friedman, M.D., President and CEO of Incyte Corporation, to its Boa
March 25 2008 - 8:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that Paul A. Friedman, M.D., President and CEO of Incyte
Corporation, has been appointed to its Board of Directors. "Sirtris
is very pleased to welcome Dr. Friedman to our Board of Directors.
Paul brings with him extensive experience in drug development and
pharmaceutical company management and will be a tremendous asset to
our organization," said Christoph Westphal, M.D., Ph.D., CEO and
Vice Chair of Sirtris Pharmaceuticals, Inc. �Sirtris� mission is to
develop new therapeutics for treating Type 2 Diabetes and other
diseases of aging,� said Paul Friedman, M.D., President and CEO of
Incyte Corporation. �I am looking forward to joining the Sirtris
Board and to actively contributing to its important mission.� In
2001, Dr. Friedman became President and Chief Executive Officer of
Incyte Corporation, a Wilmington, Delaware-based drug discovery and
development company focused on developing proprietary small
molecule drugs to treat serious unmet medical needs. Incyte's
pipeline includes multiple compounds in Phase II development for
oncology, inflammation, diabetes and HIV. Dr. Friedman served as
President of Research and Development for the DuPontMerck
Pharmaceutical Company from 1994 to 1998, and from 1998 to 2001, he
was the president of DuPont Pharmaceuticals Research Laboratories,
a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994,
Dr. Friedman served as Senior Vice President at Merck Research
Laboratories. Prior to his work at Merck and DuPont, he was
Associate Professor of Medicine and Pharmacology at Harvard Medical
School. Dr. Friedman is a diplomate of the American Board of
Internal Medicine, a member of the American Society of Pharmacology
and Experimental Therapeutics, a member of the American Society of
Clinical Investigation and a member of the American Society of
Biological Chemistry. Dr. Friedman received his A.B. in Biology
from Princeton University and his M.D. from Harvard Medical School.
About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is a
biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
the Company believes control the aging process. The Company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators for diseases of aging, such as Type 2 Diabetes
and disorders, such as MELAS; the progress and results of
pre-clinical and clinical studies of SIRT1 activators; and the
potential of sirtuin modulators to receive regulatory approval.
These forward-looking statements about future expectations, plans
and prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company's product candidates will be safe or effective, or
receive regulatory approval, the possibility that results of
pre-clinical studies are not necessarily predictive of clinical
trial results, the Company's potential inability to initiate and
complete pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024